For more: | Register for "Opportunities for the Next Administration to Advance Biomedical Innovation" webinar on Dec. 8 | FasterCures submits comments in support of MDUFA IV Commitments
December 1, 2016
FOLLOW FASTERCURES ONLINE  FacebookTwitter
FasterCures SmartBrief
Faster News for FasterCures
SIGN UP ⋅   FORWARD
Top News
House sends 21st Century Cures bill to Senate
The House voted to approve the 21st Century Cures Act, which would increase research funding, particularly for cancer, and expedite FDA reviews of drug and medical devices. Billions of dollars in new money would go to the NIH to fund research on precision medicine, cancer and neurological disorders, among other initiatives; and $1 billion in new funding would go to opioid addiction prevention and treatment programs.
The New York Times (free-article access for SmartBrief readers) (11/30),  USA Today (12/1),  Reuters (11/30) 
LinkedIn Twitter Facebook Google+ Email
  • For more:
    FasterCures applauds the bipartisan support for 21st Century Cures in the US House of Representatives. Read our full statement.
    LinkedIn Twitter Facebook Google+ Email
News from FasterCures
Register for "Opportunities for the Next Administration to Advance Biomedical Innovation" webinar on Dec. 8
FasterCures
Join FasterCures for a free webinar to discuss "Opportunities for the Next Administration to Advance Biomedical Innovation," on Thursday, Dec. 8, from 1 p.m. to 2 p.m. EST. Featured speakers include Patrick White, president, Act for NIH, and Mary Dwight, senior vice president for policy and patient programs, Cystic Fibrosis Foundation.
LinkedIn Twitter Facebook Google+ Email
 
FasterCures submits comments in support of MDUFA IV Commitments
FasterCures believes the recommendations put forward by the FDA in its Proposed MDUFA IV Commitment Letter will continue to enhance and improve the device review program as a whole. In our comments, we outline three proposed enhancements that are specifically relevant to enabling the FDA to advance its efforts to deepen and expand engagement with patients, patient advocates and family caregivers. Read our full comments.
LinkedIn Twitter Facebook Google+ Email
Learn more about FasterCures:
FasterCures Home | Milken Institute
Science and Technology
Partnering for Cures attendees forge common ground in pursuit of common cause
FasterCures' annual Partnering for Cures conference brings together leaders from across the research ecosystem to forge partnerships dedicated to improving health, and the event is distinctly different from other biopharmaceutical conferences, writes Rob Wright. "But because 'Partnering' succeeds in bringing together a wider range of potential collaborators, networkers have to find a common ground all on their own," he writes.
Life Science Leader (11/30) 
LinkedIn Twitter Facebook Google+ Email
Researchers develop cheap, easy test for blood cancer
A research team at the Fred Hutchinson Cancer Research Center says it has developed a test for chronic myeloid leukemia that uses a few dime-size spots of blood on a paper card that can be submitted through the mail. The test was spawned by a summer project for high school and college students.
The New York Times (free-article access for SmartBrief readers) (11/28) 
LinkedIn Twitter Facebook Google+ Email
Next generation of weaponized antibodies undergo testing
Clinical trials are underway on so-called weaponized antibody therapies, or antibody-drug conjugates, that deliver drugs directly to cancer cells and reduce healthy tissue damage. The approach is promising, but early versions of ADCs did not work.
Nature (free content) (11/29) 
LinkedIn Twitter Facebook Google+ Email
Finance and Economics
Patient group donates $321K for ALS research, support
ALS League Belgium donated about $321,000 to three amyotrophic lateral sclerosis research projects through an initiative that lets donors choose where their funds are spent.
ALS News Today (11/30) 
LinkedIn Twitter Facebook Google+ Email
Caltech spinoff raises $19.15M for gut-CNS therapies
Longwood Fund and Domain Associates led a Series A financing round that raised $19.15 million for Axial Biotherapeutics. The company is developing therapies licensed from the Mazmanian Lab at the California Institute of Technology that modify the patient's microbiome to treat central nervous system disorders.
MedCityNews.com (11/30) 
LinkedIn Twitter Facebook Google+ Email
Policy and Regulation
21st Century Cures bill aims to push FDA to innovate
The 21st Century Cures bill would change how the FDA regulates drugs, medical devices and biologic medicines; and authorizes the agency to spend $500 million over 10 years on innovation projects. The bill directs the FDA commissioner to seek input on which projects to pursue from the agency's Science Board and to submit a work plan within 180 days to specific House and Senate committees.
Regulatory Focus (11/28) 
LinkedIn Twitter Facebook Google+ Email
Society and Ethics
Cancer cannot be conquered without sustained, consistent funding
Policymakers worldwide must commit to building partnerships and consistently funding cancer research, experts said at an international oncology conference. "With the surge in molecular biology developments and a growing consideration for cost-benefit balance from a public health perspective, there is an increasing need to invest in cancer research and improved international partnerships to validate new targets and technologies," said Dr. Denis Lacombe, director general of the European Organisation for Research and Treatment of Cancer.
HealthDay News (11/29) 
LinkedIn Twitter Facebook Google+ Email
Protectionism could impede scientific research
Projects to develop targeted cancer treatments will fall flat unless the scientific and health care communities change how they collect, analyze and share patient data, write Richard Hamermesh and Kathy Giusti. They co-chair the Harvard Business School Kraft Precision Medicine Accelerator, which aims to promote various efforts to break down data silos and encourage collaboration and sharing.
Harvard Business Review online (tiered subscription model) (11/28) 
LinkedIn Twitter Facebook Google+ Email
No cure yet, but much to celebrate on World AIDS Day
Treatments for HIV are safer and more effective now than on the first World AIDS Day, Dec. 1, 1988, says Dr. Joel Gallant of the Southwest Care Center. About 85% of patients who get treatment are able to manage the disease, says Dr. Michael Saag, who sat with Gallant on the panel that created treatment guidelines, and CDC data show that both diagnosis and mortality rates are down.
MedPage Today (free registration) (12/1) 
LinkedIn Twitter Facebook Google+ Email
FasterCures is an action tank that works across sectors and diseases to improve the effectiveness and efficiency of the medical research enterprise. FasterCures, a center of the Milken Institute, is nonpartisan and independent of interest groups.
Contact Us
FasterCures
1101 New York Avenue, NW
Suite 620
Washington, DC 20005
(202) 336-8900 | www.fastercures.org
 
Media Inquiries
Karen Rogers
Associate Director, Communications
202.336.8919
krogers@fastercures.org
Sign Up
SmartBrief offers 200+ newsletters
Subscriber Tools:
Contact Us:
Editor  -  Lisa Gough
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2016 SmartBrief, Inc.®
Privacy policy |  Legal Information